Post-Kala-Azar Dermatosis (PKDL)

Dr. Harun Ar Rashid, MD - Arthritis, Bones, Joints Pain, Trauma, and Internal Medicine Specialist Dr. Harun Ar Rashid, MD - Arthritis, Bones, Joints Pain, Trauma, and Internal Medicine Specialist
1 View
Rx Dermatology (A-Z)

Post-kala-azar dermatosis (PKDL) is a skin condition that often follows visceral leishmaniasis (VL), a parasitic disease caused by the Leishmania parasite. While PKDL is relatively less known than VL, it is essential to understand its types, causes, symptoms, diagnostic tests, and treatment options to improve awareness and accessibility to information. In this article, we’ll break down PKDL in plain English to enhance readability, visibility on search engines, and accessibility for everyone.

Post-Kala-Azar Dermatosis (PKDL) Types:

  1. Papular PKDL: This type presents with small, raised bumps on the skin.
  2. Hypopigmented PKDL: It manifests as light-colored patches on the skin.
  3. Macular PKDL: This type is characterized by flat, discolored areas on the skin.

Causes of PKDL:

  1. Leishmania Parasite: PKDL occurs as a complication of visceral leishmaniasis, which is caused by the Leishmania parasite.
  2. Weakened Immune System: Individuals with weakened immune systems are more susceptible to developing PKDL.
  3. Genetic Factors: Some genetic factors may predispose individuals to PKDL.
  4. Environmental Factors: Living in areas with a high prevalence of VL increases the risk of PKDL.
  5. Delayed or Inadequate VL Treatment: Not treating visceral leishmaniasis promptly or effectively can lead to PKDL.
  6. Co-infections: Other infections may increase the likelihood of PKDL.
  7. Malnutrition: Poor nutrition can weaken the immune system and make PKDL more likely.
  8. Gender: PKDL is more common in males than females.
  9. Age: Children and young adults are at higher risk of developing PKDL.
  10. HIV Infection: HIV-positive individuals have an increased risk of PKDL.
  11. Immunocompromised Conditions: Diseases or medications that weaken the immune system can predispose individuals to PKDL.
  12. Prolonged Exposure: Spending a long time in VL-endemic areas can increase the risk of PKDL.
  13. Genetic Susceptibility: Certain genetic factors may make some individuals more prone to PKDL.
  14. Poor Hygiene: Lack of proper hygiene practices may contribute to PKDL.
  15. Reinfection: Being re-infected with Leishmania parasites can trigger PKDL.
  16. Crowded Living Conditions: Living in overcrowded or unhygienic environments may increase the risk.
  17. Socioeconomic Status: Individuals with lower socioeconomic status may face a higher risk.
  18. Travel History: Traveling to areas where VL is prevalent can expose individuals to the risk of PKDL.
  19. Lack of Education: Lack of awareness and education about VL and PKDL may lead to delayed treatment.
  20. Climate and Geography: Environmental factors, such as climate and geography, can influence the prevalence of VL and PKDL.

Symptoms of PKDL:

  1. Skin Rash: PKDL often starts with a skin rash consisting of small bumps or discolored patches.
  2. Hypopigmentation: Light-colored or pale skin patches may develop.
  3. Hyperpigmentation: Darker skin patches can also occur.
  4. Itching: The affected skin may be itchy and uncomfortable.
  5. Skin Lesions: Bumps or lesions may appear on the face, limbs, and body.
  6. Facial Involvement: PKDL can affect the face, leading to facial disfigurement.
  7. Mucous Membrane Involvement: In rare cases, PKDL may affect the mucous membranes, such as the mouth and nose.
  8. Eye Problems: Eye symptoms like conjunctivitis may occur in severe cases.
  9. Gradual Onset: Symptoms typically develop slowly over several months to years.
  10. Asymptomatic: Some individuals may have PKDL without noticeable symptoms.

Diagnostic Tests for PKDL:

  1. Clinical Examination: A healthcare provider examines the skin and symptoms.
  2. Skin Biopsy: A small sample of skin tissue is taken and examined under a microscope to detect Leishmania parasites.
  3. Polymerase Chain Reaction (PCR): This molecular test can detect Leishmania DNA in skin samples.
  4. Montenegro Skin Test: A skin test can determine exposure to Leishmania parasites.
  5. Blood Tests: Blood tests may reveal abnormalities associated with PKDL.
  6. History of VL: A history of visceral leishmaniasis is a strong indicator of PKDL.
  7. Differential Diagnosis: PKDL must be distinguished from other skin conditions with similar symptoms.
  8. Immunological Tests: Serological tests can detect antibodies against Leishmania.
  9. Ocular Examination: If eye symptoms are present, an eye specialist may conduct an examination.

Treatments for PKDL:

  1. Antimonials: Antimonial drugs like sodium stibogluconate or meglumine antimoniate are commonly used to treat PKDL.
  2. Amphotericin B: Liposomal amphotericin B is another effective treatment option.
  3. Miltefosine: This oral medication is used in some cases of PKDL.
  4. Phototherapy: Ultraviolet (UV) radiation therapy can help improve skin lesions.
  5. Cryotherapy: Freezing the skin lesions with liquid nitrogen can be beneficial.
  6. Topical Treatments: Creams and ointments may be prescribed to manage symptoms.
  7. Supportive Care: Proper wound care and hygiene are essential for healing.
  8. Nutritional Support: Ensuring a well-balanced diet can aid recovery.
  9. Psychological Support: Coping with the cosmetic effects may require counseling.
  10. Surveillance: Regular follow-up with healthcare providers is necessary to monitor progress.
  11. Eye Care: Ocular symptoms require specialized eye care.
  12. Infection Control: Preventing the spread of Leishmania parasites is crucial.
  13. Patient Education: Raising awareness about PKDL and its treatment is essential.
  14. Community Programs: Public health initiatives can help control PKDL in endemic regions.
  15. Research: Continued research is needed to improve treatment options.
  16. Rehabilitation: Physical therapy may be necessary for individuals with severe facial involvement.
  17. Combating Malnutrition: Addressing nutritional deficiencies is vital for recovery.
  18. Access to Healthcare: Ensuring access to healthcare services in endemic areas is crucial.
  19. Public Awareness: Educating communities about PKDL can reduce stigma.
  20. Multidisciplinary Approach: A team of healthcare professionals may be required for comprehensive care.

Drugs Used in PKDL Treatment:

  1. Sodium Stibogluconate: This antimonial drug is administered through injections and is effective against PKDL.
  2. Meglumine Antimoniate: Another antimonial, meglumine antimoniate, is used to treat PKDL.
  3. Miltefosine: This oral medication is easier to administer and has shown good results against PKDL.
  4. Amphotericin B: In severe cases, amphotericin B may be used, often intravenously.
  5. Paromomycin: This antibiotic can also be used to treat PKDL in some cases.

In Conclusion:

Post-kala-azar dermatosis (PKDL) is a skin condition that can follow visceral leishmaniasis. It manifests in various forms, including papular, hypopigmented, and macular types. PKDL can result from multiple causes, including the Leishmania parasite, weakened immune systems, genetic factors, and environmental influences. Recognizing PKDL’s symptoms, such as skin rashes and pigmentation changes, is crucial for early diagnosis.

 

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. Thank you for giving your valuable time to read the article.

  1. https://medlineplus.gov/skinconditions.html
  2. https://www.aad.org/about/burden-of-skin-disease
  3. https://www.usa.gov/federal-agencies/national-institute-of-arthritis-musculoskeletal-and-skin-diseases
  4. https://www.cdc.gov/niosh/topics/skin/default.html
  5. https://www.skincancer.org/
  6. https://illnesshacker.com/
  7. https://endinglines.com/
  8. https://www.jaad.org/
  9. https://www.psoriasis.org/about-psoriasis/
  10. https://books.google.com/books?
  11. https://www.niams.nih.gov/health-topics/skin-diseases
  12. https://cms.centerwatch.com/directories/1067-fda-approved-drugs/topic/292-skin-infections-disorders
  13. https://www.fda.gov/files/drugs/published/Acute-Bacterial-Skin-and-Skin-Structure-Infections—Developing-Drugs-for-Treatment.pdf
  14. https://dermnetnz.org/topics
  15. https://www.aaaai.org/conditions-treatments/allergies/skin-allergy
  16. https://www.sciencedirect.com/topics/medicine-and-dentistry/occupational-skin-disease
  17. https://aafa.org/allergies/allergy-symptoms/skin-allergies/
  18. https://www.nibib.nih.gov/
  19. https://rxharun.com/rxharun/rxharun/article-types/skin-care-beauty/skin-diseases-types-symptoms-treatment/
  20. https://www.nei.nih.gov/
  21. https://en.wikipedia.org/wiki/List_of_skin_conditions
  22. https://en.wikipedia.org/?title=List_of_skin_diseases&redirect=no
  23. https://en.wikipedia.org/wiki/Skin_condition
  24. https://oxfordtreatment.com/
  25. https://www.nidcd.nih.gov/health/
  26. https://consumer.ftc.gov/articles/w
  27. https://www.nccih.nih.gov/health
  28. https://catalog.ninds.nih.gov/
  29. https://www.aarda.org/diseaselist/
  30. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets
  31. https://www.nibib.nih.gov/
  32. https://www.nia.nih.gov/health/topics
  33. https://www.nichd.nih.gov/
  34. https://www.nimh.nih.gov/health/topics
  35. https://www.nichd.nih.gov/
  36. https://www.niehs.nih.gov
  37. https://www.nimhd.nih.gov/
  38. https://www.nhlbi.nih.gov/health-topics
  39. https://obssr.od.nih.gov/
  40. https://www.nichd.nih.gov/health/topics
  41. https://rarediseases.info.nih.gov/diseases
  42. https://beta.rarediseases.info.nih.gov/diseases
  43. https://orwh.od.nih.gov/

References

 

You Might Also Like This :

  1. Post-Kala-Azar Dermal Leishmaniasis (PKDL) Post-Kala-Azar Dermal Leishmaniasis (PKDL) is a rare skin condition that occurs as a complication of visceral leishmaniasis, a more severe form of the disease. PKDL can be challenging to understand, but in this article, we’ll break it down into simple terms. We’ll explain what PKDL is, its causes, symptoms, diagnostic tests, and various treatment options. […]...
  2. Linear IgA Bullous Dermatosis Linear IgA bullous dermatosis (LABD) is a rare autoimmune skin disorder that can cause uncomfortable and sometimes painful skin blisters. This article aims to provide a clear and simple explanation of LABD, covering its types, potential causes, common symptoms, diagnostic tests, available treatments, and medications. By breaking down complex medical jargon into plain English, we […]...
  3. Persistent Acantholytic Dermatosis Persistent acantholytic dermatosis is a rare skin condition that is characterized by the formation of persistent, irregularly shaped blisters or erosions on the skin. The blisters are caused by a breakdown in the cohesion of the skin cells, leading to a separation of the cells and the formation of fluid-filled spaces. This condition is often […]...
  4. Intraepidermal Neutrophilic IgA Dermatosis (IENID) Intraepidermal neutrophilic IgA dermatosis (IENID) is a rare autoimmune disorder that is characterized by the presence of IgA deposits within the epidermis. It is also known as IgA pemphigus or subcorneal pustular dermatosis. The main feature of IENID is the presence of pustules, or small blisters, on the skin that is filled with pus. This […]...
  5. Ichthyosiform Dermatosis Ichthyosiform dermatosis is a group of rare skin disorders characterized by dry, scaly skin. These conditions can be challenging to understand, so let’s break it down into simple terms. In this article, we’ll explore different types of ichthyosiform dermatosis, what causes them, their symptoms, how doctors diagnose them, available treatments, and medications used to manage […]...
  6. Dermatosis Papulosa Nigra Dermatosis Papulosa Nigra, often abbreviated as DPN, is a benign skin condition that primarily affects individuals with darker skin tones. It is characterized by small, dark, raised bumps or papules on the face and neck. While DPN is typically harmless, it can be a source of concern for those affected by it. In this article, […]...
  7. Transient Acantholytic Dermatosis (TAD) Transient acantholytic dermatosis (TAD) is a skin condition characterized by the formation of blisters and erosions on the skin that can be itchy and painful. The word “transient” refers to the temporary nature of the condition, while “acantholytic” refers to the loss of the protective outer layer of skin cells. The “dermatosis” part of the […]...
  8. Benign Papular Acantholytic Dermatosis (BPAD) Benign papular acantholytic dermatosis (BPAD) is a skin condition that is characterized by the formation of small, benign (non-cancerous) papules (raised bumps) on the skin. The papules are usually round, red, or skin-colored and can occur in various sizes and numbers. BPAD is a type of acantholytic dermatosis, which means that the skin cells (acantholysis) […]...
  9. Erosive Pustular Dermatosis of the Scalp Erosive pustular dermatosis of the scalp (EPDS) is a rare skin condition that affects the scalp and causes symptoms such as blistering, itching, and redness. This condition is considered a subtype of pustular psoriasis and is also known as Kogoj’s disease or Kogoj-Fujimoto disease. Despite the lack of information about EPDS, it is important to […]...
  10. Acquired Perforating Dermatosis Acquired perforating dermatosis is a skin condition characterized by the formation of perforations or holes in the skin. It is a relatively uncommon condition that can affect people of all ages and races. The condition is not hereditary and is acquired through various factors such as excessive sun exposure, aging, and certain underlying medical conditions. […]...
  11. Congenital Erosive Dermatosis Congenital Erosive Dermatosis (CED) is a rare genetic skin disorder that affects newborns and infants. It is characterized by painful, crusted erosions and ulcers that occur on the skin, often on the extremities, but can also be found on the trunk, face, and scalp. The exact cause of CED is unknown, but it is believed […]...
  12. Arthritis-Dermatosis Syndrome Arthritis-Dermatosis Syndrome, sometimes known as ADS, is a medical condition that affects the joints and skin. In this article, we’ll provide a simple and easy-to-understand overview of ADS, covering its types, causes, symptoms, diagnostic tests, treatments, and medications. Types of Arthritis-Dermatosis Syndrome Rheumatoid Arthritis (RA): RA is an autoimmune disorder that primarily affects the joints. […]...
  13. Subcorneal Pustular Dermatosis Subcorneal Pustular Dermatosis (SPD) is a rare skin condition. Think of it as a mysterious guest showing up at the skin party, uninvited, causing some disruptions. People with SPD will notice tiny blisters filled with pus on their skin. These blisters mainly appear on the trunk, arms, and legs. The exact cause of SPD remains […]...
  14. Scleroatrophic and Keratotic Dermatosis of the Limbs Scleroatrophic and keratotic dermatosis of the limbs are skin conditions that can cause discomfort and cosmetic concerns. These conditions often affect the arms and legs, and they can be bothersome. In this article, we’ll explain what these conditions are, what causes them, the common symptoms, how they are diagnosed, and what treatment options are available. […]...
  15. Relapsing Linear Acantholytic Dermatosis Relapsing Linear Acantholytic Dermatosis is a skin disorder characterized by recurring red patches or lines on the skin due to the separation of skin cells. Types There’s primarily one type of RLAD, but it can vary in severity and appearance from person to person. RLAD primarily comes in two main types: Darier’s Disease (DD): This […]...

To Get Daily Health Newsletter

We don’t spam! Read our privacy policy for more info.

Terms and Conditions of Use
Privacy Policy
Cookie Policy
Editorial Policy
Advertising Policy
EU User Consent Policy
Correction Policy
Citation Policy
Ethics and Logical Policies
About Us
Contact Us
Newsletter
Career
Sitemap
Advertise with us
Editorial Board Members
Review Board Member
Team RxHarun
Web Developers Team
Guest Posts and Sponsored Posts
Request for Board Member
Women Writers
Download Mobile Apps
Follow us on Social Media
© 2012 - 2025; All rights reserved by authors. Powered by Mediarx International LTD, a subsidiary company of Rx Foundation.
RxHarun
Logo